Nanobots Therapeutics

What Nanobots Therapeutics does

Nanobots Therapeutics S.L. is a preclinical-stage Spanish biotech company founded in February 2023 as a spin-off of ICREA and the Institute for Bioengineering of Catalonia (IBEC), headquartered at the Barcelona Science Park. The company develops and intends to commercialize the MotionTx platform, a class of enzyme-powered (urease) nanorobots designed to autonomously penetrate tissues and accumulate drug payloads in target cells, with a current pipeline anchored on NBT-101 for non-muscle invasive bladder cancer (NMIBC) and a second undisclosed candidate NBT-102. Its core technical differentiator is a novel mechanism of action: urease-driven nanomotors achieve 90% tumor volume reduction in preclinical bladder cancer models with a single intravesical instillation, outperforming free-drug and standard-of-care comparators, with additional proof-of-concept in STING agonist immunotherapy and siRNA gene delivery.

The go-to-market model is platform licensing to pharmaceutical partners rather than direct commercialization, with future revenue expected from licensing and royalty arrangements on therapies developed using MotionTx. To date the company has no commercial customers, no disclosed revenue, and no public pricing; commercial activity is entirely R&D-focused and supported by dilutive and non-dilutive funding. Approximately €2M+ has been raised since June 2023 via a €478K pre-seed (Sep 2023), a €960K seed first tranche (Jul 2024) backed by ESADEBAN, EconomistesBAN, BridgeBAN, BStartup de Banco Sabadell, and Prous Institute for Biomedical Research, a second seed tranche targeted at >€500K via Capital Cell crowdfunding (Nov 2024), and public grants including a €442,339 CDTI award, ACCIÓ Start-Up Capital, Torres Quevedo grants, an AGAUR Industrial Doctorate, and the AECC IMPACTO award.

Management is founder-led: Prof. Samuel Sánchez serves as Academic Founder and Interim CEO & CSO; co-founders include Andrés G Fernández (pharma drug development, ex-Almirall and Ferrer), Daniel Oliver (Capital Cell and Nara Capital venture partner), and Isaac Cabezas (CFO of Spanish unicorn Paack); Marta Soler Grima is COO. The company employs 11-50 people, holds an exclusive technology transfer from IBEC with both granted and pending patents on the platform, and has published in Nature Nanotechnology and Nature Communications in 2024.

Name

Nanobots Therapeutics

Legal name

Nanobots Therapeutics S.L.

Website

https://nanobotstx.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Nanobots Therapeutics is a preclinical Barcelona-based biotech developing the MotionTx platform of urease-powered nanobots for targeted drug delivery, with a lead program (NBT-101) in non-muscle invasive bladder cancer and a future licensing-based business model aimed at pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Nanorobotic Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

akta.pro secondary industry

Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

Keywords

• Nanorobotic therapeutics
• Targeted drug delivery
• Bladder cancer treatment
• Enzyme-powered nanomotors
• Preclinical nanomedicine

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Platform Licensing: The company plans to provide pharmaceutical industry access to its MotionTx platform technology for safer and more effective therapies to combat non-muscle invasive bladder cancer (NMIBC). This is a future revenue opportunity as the platform is still in preclinical development.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Nanobots Therapeutics develops and commercializes the MotionTx platform, a nanorobotics-based therapeutic modality in which enzyme-powered nanobots penetrate tissues and accumulate in target cells to deliver drugs with superior efficacy. The company is advancing two preclinical pipeline candidates: NBT-101 for non-muscle invasive bladder cancer (NMIBC) and NBT-102 with an undisclosed indication.

Product overview

Nanobots Therapeutics is a biotech company developing the MotionTx platform, a new modality of therapeutic entities based on nanobots that penetrate tissues with superior efficacy. The platform enables targeted drug delivery to cancer cells. The company has two pipeline candidates: NBT-101 for bladder cancer and NBT-102 with an undisclosed indication. MotionTx can carry various drugs for different therapeutic applications, with initial focus on oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• MotionTx Platform A proprietary nanorobotics platform technology enabling the development of enzyme-powered nanobots that penetrate tissues with superior efficacy, enhancing drug accumulation in target cells. The platform can carry a variety of drugs for different therapeutic indications and maximizes local routes of administration. It is intended for licensing access by pharmaceutical companies developing oncology and other therapies.
• NBT-101 A preclinical nanobot drug candidate targeting non-muscle invasive bladder cancer (NMIBC). NBT-101 uses urease-powered nanobots that penetrate the urothelium and accumulate in tumor cells, designed to provide pharmaceutical industry access to safer and more effective therapies for NMIBC patients.
• NBT-102 A preclinical nanobot drug candidate with an undisclosed therapeutic indication, representing the company's pipeline expansion using the MotionTx platform beyond the bladder cancer proof-of-concept.

Quantifiable outcome

• 90% tumor volume reduction in preclinical bladder cancer models with single intravesical instillation of urease-powered nanobots vs free drug
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• IBEC (Institute for Bioengineering of Catalonia)coreStrategic or Co-development PartnerResearch institution and original parent organization - company is a spin-off of IBEC. Provides ongoing research collaboration and exclusive technology transfer of 'Therapeutics in Motion' platform.
• ICREAcoreStrategic or Co-development PartnerInstitución Catalana de Investigación y Estudios Avanzados - company is a spin-off of ICREA with Prof. Samuel Sánchez's research program.
• CIC biomaGUNEcoreStrategic or Co-development PartnerResearch collaborator on STING agonist nanomotor project for bladder cancer immunotherapy, specializing in PET/SPECT imaging agents.
• PHI BIOMED CominorStrategic or Co-development PartnerKorean biotech company collaborating on STING agonist nanomotor research published in Nature Communications 2024.
• Seoul National University College of MedicineminorStrategic or Co-development PartnerKorean academic institution - Department of Urology collaborating on bladder cancer immunotherapy research.
• POSTECHminorStrategic or Co-development PartnerPohang University of Science and Technology (Korea) collaborating institution on nanomotor research.
• KAISTminorStrategic or Co-development PartnerKorea Advanced Institute of Science and Technology collaborating institution on nanomotor technology research.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Arcturus Therapeutics: Clinical-stage RNA therapeutics company using lipid nanoparticle (LNP) delivery technology for vaccines and rare diseases. Comparable as a platform delivery company that has validated LNP technology commercially (COVID-19 vaccine), and serves as a benchmark for how Nanobots' nanomotor approach could monetize once clinically validated.
• Bionaut Labs: US-based company developing micro/nanorobotic devices for targeted drug delivery, particularly for CNS and oncology indications. Closest peer in terms of the "nanorobotics for therapy" modality, though Bionaut focuses on externally-propelled microrobots rather than enzyme-powered autonomous nanomotors.
• Nanobiotix: French clinical-stage nanomedicine company developing nanoparticle-based therapeutics for oncology. Directly comparable as a nanotech-enabled cancer therapy platform with similar mission of improving tumor drug delivery, though at a more advanced clinical stage and using inorganic hafnium oxide nanoparticles rather than biological nanomotors.
• Selecta Biosciences (now Cartesian Therapeutics): Clinical-stage company developing immunomodulatory nanoparticles for autoimmune disease and gene therapy. Comparable as a nanoparticle-based therapeutic platform pursuing multiple indications via a single delivery technology, with similar licensing-to-pharma business model.
• Codiak BioSciences: Developer of exosome-based therapeutic platforms for oncology and inflammatory diseases. Directly comparable as a novel biological nanovesicle drug delivery platform, though Codiak wound down operations in 2023, illustrating both the opportunity and execution risk in novel delivery modalities.

Broad incumbents

• Camurus: Swedish specialty pharma company using proprietary lipid nanotech (FluidCrystal) for sustained-release drug delivery. Comparable as a commercial-stage nanotech drug delivery company, providing a useful benchmark for what Nanobots could look like once its platform reaches commercialization.
• CureVac: Clinical-stage German biotech pioneering mRNA delivery technology including proprietary nanoparticle carriers. Comparable as a European-headquartered biotech whose core value is built around an RNA/nanoparticle delivery platform, providing a regional peer and benchmark for European nanomedicine commercialization.

Emerging players

• Bio-Path Holdings: Clinical-stage company developing DNA-based therapeutics using nanoparticle delivery for oncology. Comparable as an early-stage platform company pursuing targeted nucleic acid delivery to tumors, though using a different payload class (DNAbilize technology) than Nanobots' enzyme nanomotors.
• Pharmosa Biopharm: Taiwanese clinical-stage company developing liposomal and nanotech drug delivery platforms for CNS and oncology. Comparable as a smaller, emerging nanomedicine platform company pursuing similar indication expansion strategies via proprietary delivery technology.
• Esperovax: Early-stage US biotech developing self-amplifying RNA therapeutics delivered via nanoparticle platforms. Comparable as an emerging, well-funded delivery-platform company pursuing oncology and infectious disease, with overlapping technology ambitions in targeted nanoparticle delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nanobotstx

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanobots Therapeutics